A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole.

Trial Profile

A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer; Bone metastases
  • Focus Registrational; Therapeutic Use
  • Acronyms BOLERO-2
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2017 Results assessing impact of PIK3CA mutations on everolimus efficacy published in the British Journal of Cancer.
    • 07 Jun 2016 Results (n=550) of retrospective sub-group analysis assessing the correlation of PIK3CA mutations in cell-free DNA and efficacy of everolimus presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top